Loading...
XNAS
VIVS
Market cap3mUSD
May 16, Last price  
2.07USD
1D
7.25%
1Q
-55.31%
Jan 2017
-99.75%
IPO
-99.82%
Name

Organovo Holdings Inc

Chart & Performance

D1W1MN
P/E
P/S
34.18
EPS
Div Yield, %
Shrs. gr., 5y
9.65%
Rev. gr., 5y
-48.78%
Revenues
109k
-70.54%
01,197,000379,000571,0001,483,0004,230,0004,603,0003,091,0002,196,00001,500,000370,000109,000
Net income
-15m
L-15.00%
-147,817-43,553,000-25,848,000-30,082,000-38,575,000-38,447,000-34,803,000-26,635,000-18,710,000-16,826,000-11,448,000-17,259,000-14,671,000
CFO
-15m
L+18.09%
-109,425-9,693,000-15,561,000-19,601,000-29,368,000-29,185,000-28,857,000-20,375,000-14,882,000-13,323,000-8,453,000-12,408,000-14,653,000
Earnings
May 29, 2025

Profile

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
IPO date
Aug 02, 2013
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
109
-70.54%
370
-75.33%
Cost of revenue
15,142
18,266
Unusual Expense (Income)
NOPBT
(15,033)
(17,896)
NOPBT Margin
Operating Taxes
2
2
Tax Rate
NOPAT
(15,035)
(17,898)
Net income
(14,671)
-15.00%
(17,259)
50.76%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,437
BB yield
-15.26%
Debt
Debt current
1,012
492
Long-term debt
2,282
3,118
Deferred revenue
Other long-term liabilities
Net debt
393
(12,540)
Cash flow
Cash from operating activities
(14,653)
(12,408)
CAPEX
(42)
(396)
Cash from investing activities
816
(966)
Cash from financing activities
1,437
FCF
(14,583)
(17,690)
Balance
Cash
2,901
16,007
Long term investments
143
Excess cash
2,896
16,132
Stockholders' equity
(339,659)
(324,987)
Invested Capital
345,160
342,121
ROIC
ROCE
EV
Common stock shares outstanding
9,145
8,713
Price
1.03
-52.97%
2.19
-41.76%
Market cap
9,419
-50.64%
19,082
-41.69%
EV
9,812
6,542
EBITDA
(14,753)
(17,603)
EV/EBITDA
Interest
470
Interest/NOPBT